scholarly journals The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

Diabetes Care ◽  
2019 ◽  
Vol 43 (2) ◽  
pp. e22-e24 ◽  
Author(s):  
Nishant P. Shah ◽  
Qiuqing Wang ◽  
Katherine E. Wolski ◽  
Leslie Cho ◽  
Ellen McErlean ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Medical Therapy ◽  
Optimal Medical Therapy ◽  
Residual Risk ◽  
Lipoprotein A ◽  
Post Hoc Analysis ◽  
Patients With Diabetes ◽  
Post Hoc

scholarly journals The role of High Flow Nasal Therapy in Bronchiectasis – A Post-hoc Analysis

2020 ◽  
pp. 00711-2020
Author(s):  
W. R. Good ◽  
J. Garrett ◽  
H.-U. P. Hockey ◽  
L. Jayaram ◽  
C. Wong ◽  
...  
Keyword(s):  
High Flow ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0247939
Author(s):  
Wiebe M. C. Top ◽  
Philippe Lehert ◽  
Casper G. Schalkwijk ◽  
Coen D. A. Stehouwer ◽  
Adriaan Kooy
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Natriuretic Peptide ◽  
Treatment Effect ◽  
Controlled Trial ◽  
Secondary Analysis ◽  
Initial Increase ◽  
Post Hoc Analysis ◽  
Post Hoc

Background Beyond antihyperglycemic effects, metformin may improve cardiovascular outcomes. Patients with type 2 diabetes often have an elevated plasma level of N-terminal pro B-type as a marker of (sub) clinical cardiovascular disease. We studied whether metformin was associated with a reduction in the serum level of N-terminal pro B-type natriuretic peptide (NT-proBNP) in these patients. Methods In the HOME trial 390 insulin-treated patients with type 2 diabetes were randomized to 850 mg metformin or placebo three times daily. Plasma samples were drawn at baseline, 4, 17, 30, 43 and 52 months. In a post-hoc analysis we analyzed the change in NT-proBNP in both groups. We used a longitudinal mixed model analysis adjusting for age, sex and prior cardiovascular disease. In a secondary analysis we assessed a possible immediate treatment effect post baseline. Results Metformin did not affect NT-proBNP levels over time in the primary analysis (-1% [95%CI -4;3, p = 0.62]). In the secondary analysis there was also no sustained time independent immediate treatment effect (initial increase of 17% [95%CI 4;30, p = 0.006] followed by yearly decrease of -4% [95%CI -7;0, p = 0.07]). Conclusions Metformin as compared to placebo did not affect NT-proBNP plasma levels in this 4.3-year placebo-controlled trial. Potential cardioprotective effects of metformin cannot be explained by changes in cardiac pressures or volumes to the extent reflected by NT-proBNP.

scholarly journals Role of Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: An updated meta-analysis of randomized controlled trials.

2021 ◽  
Author(s):  
Hua Ma ◽  
QIng Gu ◽  
Huining Niu ◽  
Xiaohua Li ◽  
Rong Wang
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Meta Analysis ◽  
Significant Risk ◽  
Diabetic Patients ◽  
Primary Endpoints ◽  
All Cause Mortality ◽  
Patients With Diabetes ◽  
Rule Out

Background: The use of Aspirin in the primary prevention of cardiovascular disease (CVD) is still a topic of debate, especially in patients with diabetes. The present meta-analysis aims to rule out the efficacy of Aspirin in patients with diabetes and to compare the effectiveness of Aspirin with a placebo (or no treatment) for the primary prevention of CVD and all-cause mortality events in people with diabetes. Materials and Methods: An extensive and systematic search was conducted in Medline (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020. A detailed literature search was conducted using Aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received Aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The risk of bias (RoB) in included studies was evaluated using the QUADAS-2 tool. Results: A total of 5 studies out of 13 were included with 23,570 diabetic patients; 11,738 allocated to Aspirin and 11,832 allocated to the placebo group. In patients with diabetes, there was no difference between Aspirin and placebo with respect to the risk of all-cause death with a confidence interval (CI) varying 0.63 to 1.17. In addition, there were no differences in the bleeding outcomes with an odds ratio of 1.4411 (CI 0.47 to 4.34). Conclusion: Aspirin has no significant risk on primary endpoints of cardiovascular events and the bleeding outcomes in diabetic patients compared to placebo. More research on the use of Aspirin alone or in combination with other antiplatelet drugs is required in patients with diabetes to supplement currently available research.

scholarly journals 1550P A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients

2021 ◽  
Vol 32 ◽  
pp. S1125-S1126
Author(s):  
R.W. Hamacher ◽  
X. Liu ◽  
M.K. Schuler ◽  
L. Hentschel ◽  
P. Schöffski ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Prognostic Role ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document